This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: June 27, 2007
Last updated: March 1, 2016
Last verified: March 2016
This 2 arm study will assess the efficacy and safety of intravenous Bonviva in patients with osteoporosis experiencing pain after recent vertebral osteoporotic fracture. Patients will be randomized to receive either Bonviva (3mg i.v. bolus injection) or placebo. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Osteoporosis Drug: Placebo Drug: ibandronate [Bonviva/Boniva] Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind Study of the Efficacy of Intravenous Bonviva in the Relief of Pain After Recent Vertebral Osteoporotic Fracture in Osteoporotic Patients.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Success of Bonviva therapy (>=20% diminution of pain intensity between day 0 and 7, with stabilization or diminution of concomitant analgesics between day 3 and 7). [ Time Frame: Day 7 ]

Secondary Outcome Measures:
  • Percentage of patients with >=50% diminution of pain between day 0 and 7 [ Time Frame: Day 7 ]
  • Pain control [ Time Frame: Day 7 and 1 month ]
  • Analgesic medication [ Time Frame: 1 month ]
  • Hospitalization [ Time Frame: 1 month ]
  • AEs and laboratory parameters [ Time Frame: Throughout study ]

Enrollment: 68
Study Start Date: June 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ibandronate [Bonviva/Boniva]
3mg i.v. single dose
Placebo Comparator: 2 Drug: Placebo
Placebo i.v. single dose


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • postmenopausal women or men >30 years of age;
  • osteoporosis;
  • vertebral osteoporotic fracture in past 4 weeks;
  • fracture-related pain requiring analgesic treatment.

Exclusion Criteria:

  • non-menopausal women;
  • current treatment with another bisphosphonate;
  • current treatment with class III analgesics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00493623

Aix En Provence, France, 13616
Amiens, France, 80054
Angers, France, 49033
Bonneville, France, 74136
Bordeaux, France, 33076
Caen, France, 14033
Cannes, France, 06401
Clermont-ferrand, France, 63003
Echirolles, France, 38434
Lille, France, 59037
Lomme, France, 59462
Marseille, France, 13285
Marseille, France, 13385
Montpellier, France, 34295
Mulhouse, France, 68070
Nantes, France, 44035
Nice, France, 06202
Orleans, France, 45000
Paris, France, 75181
Paris, France, 75475
Paris, France, 75571
Paris, France, 75651
Paris, France, 75674
Rennes, France, 35203
Rouen, France, 76031
Saint-priest En Jarez, France, 42277
Toulouse, France, 31059
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00493623     History of Changes
Other Study ID Numbers: ML19360
Study First Received: June 27, 2007
Last Updated: March 1, 2016

Additional relevant MeSH terms:
Osteoporotic Fractures
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Fractures, Bone
Wounds and Injuries
Ibandronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017